Is radiotherapy a back up plan after neoadjuvant chemo-immunotherapy in perioperative lung cancer management?

Perioperative anti–PD-L1 therapy improves event-free survival in resectable NSCLC with ctDNA-based risk stratification

Machine learning models improve prediction of immunotherapy outcomes across multiple cancer types

Setidegrasib shows promising activity in KRAS G12D-mutated advanced NSCLC

The potential of T-cell engagers in SCLC treatment

Development and challenges for T-cell engagers as a novel treatment for lung cancer and mesothelioma

Cemiplimab shows durable 6-year survival benefit in PD-L1 high advanced NSCLC

MK-1084 plus pembrolizumab achieves high response rates in KRAS G12C mutated non-small cell lung cancer

Durvalumab plus chemotherapy improves survival in extensive-stage small cell lung cancer regardless of tumour laterality

Durvalumab improves survival and delays progression in limited-stage small cell lung cancer

Osimertinib plus local therapy improves outcomes in EGFR-mutant metastatic lung cancer

Pembrolizumab plus chemotherapy delivers lasting benefit in early-stage NSCLC